Updated results from a Phase I/IIa studies carried out on SRA737 by licensing partner Sierra Oncology will be delivered in the form of two abstracts at the American Society of Clinical Oncology (ASCO) annual meeting in Chicago on June 1.
The Sareum-discovered drug candidate is what’s known as a checkpoint kinase 1 (CHK1) inhibitor.
CHK1 controls a cancer cell's response to DNA damage, which could be caused by the disease itself or intentionally by chemotherapy or radiotherapy.
The new treatment is being trialled in women with ovarian cancer, both as a single therapy and in harness with chemotherapy called gemcitabine.
The ASCO abstracts cover new data on the two approaches to treating the killer disease.
In afternoon trading, Sareum shares were 7.1% higher at 0.75p.
-- Adds share price --